Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GABRP | O00591 | 3/20 | 0.36 |
| ▸ | GABRD | O14764 | 3/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.36 |
| ▸ | GABRE | P78334 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D-Allothreonine SCHEMBL222076 | 1.00 | — | — | |
| Threonine SCHEMBL16111860 | 1.00 | SLC7A5 (0.63) | SLC7A5TP53SLC1A3SLC1A2SLC1A1 | |
| Threonine SCHEMBL9461237 | 1.00 | SLC7A5 (0.63) | SLC7A5TP53SLC1A3SLC1A2SLC1A1 | |
| Threonine SCHEMBL92730 | 1.00 | — | — | |
| Threonine SCHEMBL14946556 | 1.00 | — | — | |
| Threonine SCHEMBL2702066 | 1.00 | SLC7A5 (0.63) | SLC7A5TP53SLC1A3SLC1A2SLC1A1 | |
| Threonine SCHEMBL18050157 | 1.00 | SLC7A5 (0.63) | SLC7A5TP53SLC1A3SLC1A2SLC1A1 | |
| Threonine SCHEMBL18050155 | 1.00 | SLC7A5 (0.63) | SLC7A5TP53SLC1A3SLC1A2SLC1A1 | |
| Threonine SCHEMBL117301 | 1.00 | — | — | |
| Threonine SCHEMBL1480 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060281897-A1 | Potentialization of the activation of high molecular weight prodrugs | DIATOS S.A. (FR) | 2006-12-14 | — | — | US | disclosed |
| EP-1701743-A2 | POTENTIATION OF THE ACTIVATION OF HIGH-MOLECULAR-MASS PRODRUGS | Diatos (FR) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005021043-A2 | HIGH-MOLECULAR-MASS PRODRUGS | DIATOS (FR) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281897-A1 | Potentialization of the activation of high molecular weight prodrugs | CD44, MMP12, FOLH1 | SLC7A5 523/4885TP53 94/4885SLC1A3 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.